There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Supernus Pharmaceuticals (SUPN) and Rhythm Pharmaceuticals Inc (RYTM) with bullish sentiments.
Supernus Pharmaceuticals (SUPN)
Mizuho Securities analyst Irina Rivkind Koffler reiterated a Buy rating on Supernus Pharmaceuticals today and set a price target of $61. The company’s shares opened today at $43.03.
According to TipRanks.com, Koffler is a 4-star analyst with an average return of 8.0% and a 43.1% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Supernus Pharmaceuticals is a Strong Buy with an average price target of $56.75, which is a 31.9% upside from current levels. In a report issued on November 7, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $57 price target.
.
See today’s analyst top recommended stocks >>
Rhythm Pharmaceuticals Inc (RYTM)
Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Rhythm Pharmaceuticals Inc today and set a price target of $40. The company’s shares opened today at $25.82.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 5.3% and a 44.8% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Allogene Therapeutics Inc, and Voyager Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Rhythm Pharmaceuticals Inc with a $38 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
